166 related articles for article (PubMed ID: 17270361)
1. Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation.
Cohen IJ
Med Hypotheses; 2007; 68(5):1147-53. PubMed ID: 17270361
[TBL] [Abstract][Full Text] [Related]
2. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Cohen IJ
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1057-1065. PubMed ID: 28455583
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
Vezmar S; Schüsseler P; Becker A; Bode U; Jaehde U
Pediatr Blood Cancer; 2009 Jan; 52(1):26-32. PubMed ID: 19006245
[TBL] [Abstract][Full Text] [Related]
4. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.
Cohen IJ
J Pediatr Hematol Oncol; 2004 Mar; 26(3):156-63. PubMed ID: 15125607
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates.
Rosenblatt DS; Whitehead VM; Matiaszuk NV; Pottier A; Vuchich MJ; Beaulieu D
Mol Pharmacol; 1982 May; 21(3):718-22. PubMed ID: 6180291
[TBL] [Abstract][Full Text] [Related]
6. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
7. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment.
Fan C; Cool JC; Scherer MA; Foster BK; Shandala T; Tapp H; Xian CJ
Bone; 2009 Jan; 44(1):61-70. PubMed ID: 18976724
[TBL] [Abstract][Full Text] [Related]
8. Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols.
Goldman ID; Gupta V; White JC; Loftfield S
Cancer Res; 1976 Jan; 36(1):276-9. PubMed ID: 1248006
[TBL] [Abstract][Full Text] [Related]
9. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?
Cohen IJ; Wolff JE
Pediatr Blood Cancer; 2014 Jan; 61(1):7-10. PubMed ID: 24038885
[TBL] [Abstract][Full Text] [Related]
10. [Neurotoxicity due to methotrexate in paediatric patients. Description of the clinical symptoms and neuroimaging findings].
Garcia-Puig M; Fons-Estupina MC; Rives-Sola S; Berrueco-Moreno R; Cruz-Martinez O; Campistol J
Rev Neurol; 2012 Jun; 54(12):712-8. PubMed ID: 22673947
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
Sadée W
Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
[TBL] [Abstract][Full Text] [Related]
12. High-dose leucovorin reverses acute high-dose methotrexate neurotoxicity in the rat.
Phillips PC; Thaler HT; Allen JC; Rottenberg DA
Ann Neurol; 1989 Apr; 25(4):365-72. PubMed ID: 2785366
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid.
Padmanabhan S; Tripathi DN; Vikram A; Ramarao P; Jena GB
Mutat Res; 2009 Feb; 673(1):43-52. PubMed ID: 19110071
[TBL] [Abstract][Full Text] [Related]
14. The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study.
Bonda-Shkedi E; Arush MW; Kaplinsky C; Ash S; Goshen Y; Yaniv I; Cohen IJ
J Pediatr Hematol Oncol; 2013 May; 35(4):271-5. PubMed ID: 23612378
[TBL] [Abstract][Full Text] [Related]
15. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.
Drachtman RA; Cole PD; Golden CB; James SJ; Melnyk S; Aisner J; Kamen BA
Pediatr Hematol Oncol; 2002; 19(5):319-27. PubMed ID: 12078863
[TBL] [Abstract][Full Text] [Related]
16. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
[TBL] [Abstract][Full Text] [Related]
18. Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand.
Bhurani D; Schifter M; Kerridge I
Bone Marrow Transplant; 2008 Oct; 42(8):547-50. PubMed ID: 18622418
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
[TBL] [Abstract][Full Text] [Related]
20. A radioimmunoassay for methotrexate and its comparison with spectrofluorimetric procedures.
Loeffler LJ; Blum MR; Nelsen MA
Cancer Res; 1976 Sep; 36(9 pt.1):3306-11. PubMed ID: 1086132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
